EGFR and breast cancer: Lapatinib, a dual EGFR HER2 inhibitor used in the treatment of HER2-positive breast cancer has a half-life of 24 h (51) whilst the monoclonal HER2 antibody trastuzumab also used in HER2-positive breast cancer has a half-life of over 5 days (52).